Gilead’s Magrolimab Hit With Third Clinical Hold, This Time In AML

Gilead’s novel immune checkpoint inhibitor candidate, magrolimab, has been placed on a partial clinical hold by the US Food and Drug Administration in acute myeloid leukemia, adding to a spate of recent setbacks for the therapy that are chipping away at investor confidence.  

silhouette of man trying to hold up row of dominoes falling down
Magrolimab Could Succeed In AML Despite The Hold • Source: Shutterstock

Gilead Sciences, Inc.’s first-in-class immunotherapy candidate, magrolimab, has been hit with a partial clinical hold from the US Food and Drug Administration in acute myeloid leukemia (AML), less than a month after it discontinued a pivotal trial of the drug in myelodysplastic syndromes (MDS).

More from Clinical Trials

More from R&D

Moderna Punts On US Vaccine Policy Changes, Will Focus More On Cancer

 
• By 

On its Q1 earnings call, Moderna avoided criticizing policy changes affecting vaccines but de-emphasized its flu/COVID-19 vaccine for under-50 and prioritized cancer programs.

Could There Be A Cure For Cardiometabolic Disease? Novo Nordisk Foundation Wants To Help Academics Find Out

 

The not-for-profit’s senior vice president Martin Ridderstråle explains how it is expanding grants for basic research to improve "human and planetary" health.

GSK Talks Up Nucala COPD Hospitalization Data In Challenge To Dupixent

 
• By 

As the PDUFA date for the UK major’s IL-5 inhibitor draws close.